We spoke to Professor Freek Verheugt (The Heart-Lung Centre, University Medical Centre, Nijmegen and Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands) at C3 2019 about the findings from the recently released ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 (STOPDAPT-2) and the Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES (SMART-CHOICE) studies, and how they might impact routine practice.
Speaker’s Disclosures: Freek Verheugt is an advisor to AstraZeneca.
Questions:
1. How do you interpret the findings from the recently released Short and Optimal Duration of Dual Antiplatelet Therapy-2 Study (STOPDAPT-2), and how do you think they may be incorporated into routine practice? (0:04)
2. What were your impressions of the findings of the Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES (SMART-CHOICE) study, and what impact do you think they might have in practice? (3:05)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed in partnership with C3 at the 2019 annual meeting in Orlando, Florida, June 2019.
